Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation, Dose-expansion and Efficacy Extension Phase I/II Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of WJB001 Combination Therapy in Patients With Advanced Solid Tumors

NCT06953323 is registered in ClinicalTrials.gov with Wigen Biomedicine Technology (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT06953323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06953323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation, Dose-expansion and Efficacy Extension Phase I/II Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of WJB001 Combination Therapy in Patients With Advanced Solid Tumors
Lead sponsor
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 10, 2025
Completion date
December 30, 2029
Enrollment
86 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor